# Trial of pIL-12 Electroporation Malignant Melanoma

> **NCT01502293** · PHASE2 · COMPLETED · sponsor: **OncoSec Medical Incorporated** · enrollment: 51 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Tavokinogene Telseplasmid (tavo)
- **DEVICE:** OncoSec Medical System (OMS)

## Key facts

- **NCT ID:** NCT01502293
- **Lead sponsor:** OncoSec Medical Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-14
- **Primary completion:** 2016-03-21
- **Final completion:** 2016-03-21
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01502293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01502293, "Trial of pIL-12 Electroporation Malignant Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01502293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*